NASDAQ:CDMO - Avid Bioservices Stock Price, Forecast & News

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Avid Bioservices shares reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices Inc (NASDAQ:CDMO) announced its quarterly earnings data on Monday, December, 9th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $18.31 million during the quarter, compared to analysts' expectations of $14.34 million. Avid Bioservices had a negative return on equity of 8.78% and a negative net margin of 6.83%. The business's revenue was up 79.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) earnings per share. View Avid Bioservices' Earnings History.

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Avid Bioservices.

5 equities research analysts have issued 1-year target prices for Avid Bioservices' shares. Their forecasts range from $7.50 to $11.00. On average, they anticipate Avid Bioservices' share price to reach $9.90 in the next year. This suggests a possible upside of 46.7% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

Media headlines about CDMO stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avid Bioservices earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Avid Bioservices.

Some companies that are related to Avid Bioservices include Corcept Therapeutics (CORT), Endo International (ENDP), Nabriva Therapeutics (NBRV), Intra-Cellular Therapies (ITCI), BELLUS Health (BLUSF), TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Dicerna Pharmaceuticals (DRNA), Y-mAbs Therapeutics (YMAB), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Athenex (ATNX), Myovant Sciences (MYOV), ZEALAND PHARMA/S (ZEAL) and NextCure (NXTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Biopharma (ARRY), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), SLS International (SLS), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA) and Netflix (NFLX).

Avid Bioservices' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janney Montgomery Scott LLC (0.07%). Company insiders that own Avid Bioservices stock include Joel Mccomb, Joseph Carleone, Mark R Bamforth and Richard B Hancock. View Institutional Ownership Trends for Avid Bioservices.

CDMO stock was bought by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Joseph Carleone, Mark R Bamforth and Richard B Hancock. View Insider Buying and Selling for Avid Bioservices.

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDMO stock can currently be purchased for approximately $6.75.

Avid Bioservices has a market capitalization of $380.30 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.View Additional Information About Avid Bioservices.

The official website for Avid Bioservices is http://www.avidbio.com/.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]